Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03865472
Other study ID # i 65718
Secondary ID NCI-2018-03300i
Status Recruiting
Phase N/A
First received
Last updated
Start date November 10, 2018
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source Roswell Park Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies best dose and how well repetitive transcranial magnetic stimulation (rTMS) works in promoting smoking cessation and preventing relapse in current smokers. rTMS is a form of brain stimulation therapy that controls nerve cell activity, increases blood flow in the brain, and improves cognitive function.


Description:

PRIMARY OBJECTIVES: I. To examine the effects of stimulation duration (stimulation days) and intensity (pulses per day) on outcomes among smokers (sample size [n]=258) motivated to quit. II. To identify the most promising dosing strategy by balancing effect sizes and undesirable effects. III. To examine the effects of 16 20Hz rTMS sessions combined with intensive cognitive behavioral treatment and nicotine replacement on smoking cessation, developmental disability (DD rates), cognitive behavioral skill acquisition, and nicotine patch adherence among lung cancer (LC) patients (n=30). (Study 1 and Study 2) IV. To examine the feasibility and potential efficacy of 20Hz rTMS on the left dorsolateral prefrontal cortex (DLPFC) for concurrent smoking abstinence and reductions in alcohol use among smokers who are heavy drinkers (n=20). (Study 1 and Study 2) OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo rTMS once daily (QD) or twice daily (BID) over 16 minutes for 8, 12, or 16 days. ARM II: Patients undergo sham rTMS QD or BID over 16 minutes for 8, 12, or 16 days.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants will be right-handed lung cancer patients - Negative urine drug screen at the baseline assessment - Ability to read at the 8th grade level - Passes the Transcranial Magnetic Stimulation Adult Safety and Screening Questionnaire (TASS) - Participants must smoke between 5 and 25 cigarettes per day with the intent to quit smoking in the next 30 days - Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure - Study 1: Participants will be right-handed lung cancer or head and neck cancer patients - Study 1: Age 18+ - Study 1: Negative urine drug screen at the baseline assessment - Study 1: Ability to read at the 8th grade level - Study 1: Passes the Transcranial Magnetic Stimulation Adult Safety and Screening Questionnaire (TASS) - Study 1: Participants must smoke at least 4 cigarettes per day and intend to quit smoking in the next 60 days - Study 1: Is a patient - with primary non-small and small cell LC or with primary non-skin squamous cell HNC - Study 2: Participants will be healthy right-handed adults - Study 2: Age 18-65 years old - Study 2: Negative urine drug screen at the baseline assessment - Study 2: Ability to read at the 8th grade level - Study 2: Passes the Transcranial Magnetic Stimulation Adult Safety and Screening Questionnaire (TASS) - Study 2: Participants must smoke between 5 and 25 cigarettes per day with the intent to quit smoking in the next 30 days - Study 2: Meet the criteria for heavy alcohol use: > 7 drinks per week for women, > 15 drinks per week for men OR binge drinking >= 5 days in the past month. Binge drinking is defined as >= 4 drinks for women and >= 5 drinks for men, consumed within 2 hours of each other - Study 2: Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: - Has a personal history of epilepsy - Has a history of anticonvulsant medication use - Has a personal history of head injury - Has a History of aneurysm, stroke, or previous cranial neurosurgery or abnormal findings on the magnetic resonance imaging (MRI) (e.g., tumor, aneurism, etc.) - Has uncontrolled major depressive disorder, bipolar disorder or a schizophrenia-spectrum disorder, or tinnitus - Has any metal implants or neuro-stimulators in the head, neck, or cochlea - Has a pacemaker - Personal history of migraine headaches - Currently taking medications that lower seizure threshold (e.g., such as tricyclic antidepressants or bupropion) - Currently using medications for tobacco cessation (e.g., nicotine replacement, bupropion, varenicline, etc) - Pregnant or planning to become pregnant in the next 24 weeks - Current regular use of forms of tobacco other than cigarettes including e-cigarettes - Participants who score above 48.3 on the Claustrophobia Questionnaire at the baseline assessment will be excluded because they are likely to be unable to undergo an magnetic resonance imaging (MRI) without distress - Individuals who score >15, indicative of moderate-severe Alcohol Use Disorder, on the Alcohol Use Disorders Identification Test (AUDIT). - Unwilling or unable to follow protocol requirements - Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to participate in the study - Study 1:Has a personal history of Brain metastases - Study 1: Unable to use nicotine patches - Study 1: Has a Personal history of epilepsy - Study 1: Has a History of anticonvulsant medication use - Study 1: Has a Personal history of head injury - Study 1: History of aneurysm, stroke, or previous cranial neurosurgery or abnormal findings on the MRI (e.g., tumor, aneurism, etc.) - Study 1: A diagnosis of major depressive disorder, bipolar disorder or a schizophrenia-spectrum disorder, or tinnitus - Study 1: Has any Metal implants or neuro-stimulators in the head, neck, or cochlea - Study 1: Has a pacemaker - Study 1: Personal history of Migraine headaches - Study 1: Currently taking medications that lower seizure threshold (e.g., such as tricyclic antidepressants or bupropion) - Study 1: Currently using bupropion or varenicline for smoking cessation - Study 1: Pregnant or planning to become pregnant in the next 24 weeks - Study 1: Current regular use of forms of tobacco other than cigarettes - Study 1: Participants who score above 48.3 on the Claustrophobia Questionnaire at the baseline assessment will be excluded because they are likely to be unable to undergo a magnetic resonance imaging (MRI) scan without distress - Study 1: Unwilling or unable to follow protocol requirements - Study 1: Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to participate in the study - Study 2: Has a personal history of epilepsy - Study 2: Has a history of anticonvulsant medication use - Study 2: Has a personal history of head injury - Study 2: Has a history of aneurysm, stroke, or previous cranial neurosurgery or abnormal findings on the MRI (e.g., tumor, aneurism, etc.) - Study 2: Has a diagnosis of major depressive disorder, bipolar disorder or a schizophrenia-spectrum disorder, or tinnitus - Study 2: Has any metal implants or neuro-stimulators in the head, neck, or cochlea - Study 2: Has a pacemaker - Study 2: Personal history of Migraine headaches - Study 2: Currently taking medications that lower seizure threshold (e.g., such as tricyclic antidepressants or bupropion) - Study 2: Currently using medications for tobacco cessation (e.g., nicotine replacement, bupropion, varenicline, etc.) - Study 2: Pregnant or planning to become pregnant in the next 24 weeks - Study 2: Current regular use of forms of tobacco other than cigarettes - Study 2: Participants who score above 48.3 on the Claustrophobia Questionnaire at the baseline assessment will be excluded because they are likely to be unable to undergo a magnetic resonance imaging (MRI) without distress - Study 2: Meet the criteria for severe alcohol use disorder (AUD) (> 6 symptoms) or have ever met Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-V) criteria for alcohol withdrawal. Heavy drinking and AUD are not mutually exclusive. - Study 2: Unwilling or unable to follow protocol requirements - Study 2: Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to participate in the study

Study Design


Intervention

Other:
Questionnaire Administration
Ancillary studies
Procedure:
Repetitive Transcranial Magnetic Stimulation
Undergo rTMS
Sham Intervention
Undergo sham rTMS

Locations

Country Name City State
United States Roswell Park Cancer Institute Buffalo New York

Sponsors (2)

Lead Sponsor Collaborator
Roswell Park Cancer Institute National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Latency to relapse Latency to relapse will be defined as the number of days from the quit day to relapse. Relapse will be defined as smoking for seven consecutive days. Will use Cox proportional-hazards (CPH) models to examine latency to relapse outcome. Ties in failure times will be handled using methods developed by Efron. Compliance with the CPH assumptions will be tested by coding the factors as time-dependent covariates. Up to 30 days
Secondary Point-prevalence abstinence rates Will use logistic regression models to examine binary 12 and 24-week point prevalence abstinence. At 12 and 24 weeks after quit date
Secondary Delay discounting rates Will be examined through using repeated measures Generalized Linear models. At 12 and 24 weeks after quit date
Secondary Cognitive-behavioral Therapy Skills Questionnaire Cognitive behavioral skills will be assessed using the Cognitive-Behavioral Therapy Skills Questionnaire (CBTSQ) Up to 24 weeks
Secondary Side effects Potential undesirable effects will be measured up to 24 weeks. Up to 24 weeks
Secondary Forever Free (FF) Booklet content Exposure Will be measured in terms of number of content segments in each booklet. Up to 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03691350 - Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs Early Phase 1
Completed NCT01967082 - APPSPIRE App in Preventing Students From Smoking N/A
Active, not recruiting NCT02271919 - Varenicline and Combined NRT for Smoking Cessation Phase 4
Withdrawn NCT03668769 - Quitting Schedule Mobile Smartphone Application in Helping Participants to Quit Smoking N/A
Completed NCT02575885 - Nicotine Delivery From Novel Non-Tobacco Electronic System in Smokers N/A
Completed NCT04060446 - Effects of Filter Ventilation on Sensory Response, Smoking Topography, and Inhalation in Current Every Day Cigarette Smokers
Completed NCT00941395 - Enhanced Smoking Cessation for University Students N/A
Recruiting NCT03199651 - Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer N/A
Recruiting NCT03824535 - 18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules Phase 2
Completed NCT00468234 - Validation of Biomarkers of Exposure and Host Response N/A
Completed NCT00850954 - Project CASA in Promoting Smoke-Free Indoor Air Policy in Mexican American Households N/A
Active, not recruiting NCT02697227 - Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation N/A
Completed NCT03669120 - Tailored Smoking Cessation Intervention in Promoting Sexual and Gender Minority Smokers to Quit Smoking N/A
Completed NCT00948129 - Mobile Smoking Cessation Intervention in Enhancing Cancer Outreach in Low-Income Adult Smokers N/A